I agree that MSB should unambiguously state if Teva saw the yes/no from the surrogate endpoint analysis, and they should release it to the ASX, not via an email.
I haven't seen any FDA ruling that this data couldn't be released to Teva, especially since it has been part of the trial design from the beginning. Can you find a source?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
-0.053(3.13%) |
Mkt cap ! $2.063B | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.68 | $1.62 | $4.793M | 2.930M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 100322 | $1.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.63 | 14827 | 27 |
View Market Depth
| Last trade - 13.05pm 03/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |